查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
细胞和基因治疗製造服务市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按类型、适应症、应用、最终用户和地理位置
市场调查报告书
商品编码
1362428

细胞和基因治疗製造服务市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按类型、适应症、应用、最终用户和地理位置

Cell and Gene Therapy Manufacturing Services Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type, Indication, Application, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 216 Pages | 订单完成后即时交付

价格

细胞和基因治疗製造服务市场规模预计将从2022年的75.8197亿美元增长到2030年的26​​7.249亿美元；预计 2022-2030 年复合年增长率为 17.1%。

该报告强调了市场的普遍趋势以及推动和阻碍细胞和基因治疗製造服务市场成长的因素。市场的成长归因于细胞和基因疗法批准数量的增加以及外包细胞和基因疗法製造的日益普及。然而，细胞和基因疗法製造的高成本阻碍了市场的成长。

公司的策略倡议

在细胞和基因治疗製造服务市场中运营的公司专注于策略发展，例如合作、扩张、协议、伙伴关係和新产品发布，这有助于他们提高销售、扩大地理覆盖范围并增强迎合市场需求的能力。比现有的客户群更大。以下提到了细胞和基因治疗製造服务市场的一些值得注意的发展。

2023 年 5 月，Lonza 推出了 TheraPEAK T-VIVO 细胞培养基，采用新型化学成分确定的配方，旨在优化和简化 CAR T 细胞的製造。与其他无血清培养基不同，TheraPEAK T-VIVO 细胞培养基无需添加人类血清或其成分即可表现出高性能。

2022年10月，辉瑞公司完成了对Biohaven Pharmaceutical Holding Company Ltd.的收购，Biohaven Pharmaceutical Holding Company Ltd.是NURTEC ODT（rimegepant）的製造商，NURTEC ODT（rimegepant）是一种创新的偏头痛疗法，被核准用于成人发作性偏头痛的急性治疗和预防。

2022 年 3 月，Cellevolve Bio 与西雅图儿童治疗公司合作，开发和商业化用于儿童癌症的新型多重 CAR。根据此次合作，合作伙伴将专注于 BrainChild 研究项目，该项目由五种多重 CAR 组成，用于治疗儿童中枢神经系统 (CNS) 恶性肿瘤。透过合作，他们将利用西雅图儿童治疗工厂设施对新 CAR 进行早期临床 GMP 研究。

2022 年 3 月，Twist Bioscience Corporation 和 Kriya Therapeutics, Inc. 签署了一项抗体发现协议，在肿瘤治疗应用中使用腺相关病毒 (AAV) 基因疗法递送抗体。合作后，两家公司计划将 Twist 的抗体库与 Kriya 的专有载体工程平台结合，以发现针对特定目标的新型抗体，并透过 Kriya 的基因治疗技术提供。

2022 年 2 月，Edigene Inc. 与波士顿儿童医院 (BCH) 签订了一项全球许可协议，涉及透过破坏关键基因来上调胎儿血红蛋白的智慧财产权。胎儿血红蛋白的上调是治疗由异常血红蛋白结构（血红蛋白病）引起的许多遗传性疾病的潜在治疗方法，用胎儿版本的血红蛋白分子替换有缺陷的血红蛋白分子。

2022 年 1 月，富士胶片公司同意从 Atara Biotherapeutics, Inc. 收购一家细胞疗法製造工厂。该工厂易于扩展，能够灵活地生产临床和商业细胞疗法，包括同种异体 T 细胞和 CAR T 免疫疗法。

2021 年 1 月，赛默飞世尔科技公司收购了 Groupe Novasep SAS 旗下位于比利时的病毒载体製造业 Henogen SA。 Henogen 为生物技术公司和大型生物製药客户提供疫苗和治疗药物製造服务。透过此次收购，赛默飞世尔科技扩大了在细胞和基因疫苗及疗法领域的能力。

因此，推出病毒载体、细胞治疗製造培养基及同种异体T细胞等产品；开发针对各种健康问题的创新产品，以创造新的或改进的产品；透过合作和伙伴关係启动新业务以保持市场竞争力，所有这些都有助于加速细胞和基因治疗製造服务新平台的开发。因此，这些策略措施为细胞和基因治疗製造服务市场创造了巨大的成长机会。

细胞和基因疗法製造成本高昂

由于细胞和基因疗法涉及复杂的製造过程并使用生物成分，因此这些疗法的价格过高。例如，Kymriah 的成本约为 475,000 美元，Yescarta 的成本约为 373,000 美元。根据临床与经济评论研究所（ICER）的分析，基因治疗的平均成本为每剂100-200万美元。细胞和基因疗法的製造涉及各种风险，例如黑盒子效应、放大失败和灵活性降低。黑盒效应是指在自动化系统中执行的任务和流程；进程不可见，且进度状态被隐藏。因此，缺乏对製造过程的可见性会增加故障并降低适应製造过程的灵活性。此外，製造商面临的最严峻的挑战是获得 FDA 和 EMA 等监管机构的产品批准，并确保患者的安全免受治疗副作用的影响。

此外，耗材和设备的成本要高得多，这导致细胞疗法的成本高。例如，Miltenyi Biotec 提供的试剂盒价格从 500 美元到 5,000 美元不等。同样，安装设备的资本成本也接近200万美元。因此，与治疗价格有关的挑战限制了细胞和基因治疗製造服务市场的成长。

细胞和基因治疗製造服务市场，按类型分析

根据类型，细胞和基因治疗製造服务市场分为细胞治疗和基因治疗。细胞疗法分为自体细胞疗法和同种异体细胞疗法。此外，基因治疗分为病毒载体和非病毒载体。细胞治疗领域在 2022 年占据更大的市场份额。然而，基因治疗领域预计在预测期内（2022-2030 年）复合年增长率最高，达到 16.6%。基因疗法是一种利用基因来预防、治疗或治癒医学病症或疾病的技术。基因疗法通常透过用健康版本的基因替换患者细胞中的缺陷基因或添加损坏或缺失基因的新副本来发挥作用。基因疗法可用于修改体内和体外的细胞。当使用基因疗法修改体内细胞时，将携带基因的载体直接注射到患者体内。而当基因疗法用于修改体外细胞并在实验室中分离特定细胞类型时，会取出血液、骨髓或其他组织。

细胞和基因治疗製造服务市场，透过基于适应症的洞察

根据适应症，细胞和基因治疗製造服务市场分为癌症、骨科等。到 2022 年，癌症细分市场占据最大市场份额，预计该细分市场在预测期内将以最高复合年增长率成长。细胞和基因治疗的广泛领域有望带来许多有潜力预防癌症死亡的创新疗法。根据癌症基因治疗联盟 2022 年 4 月通讯报道，美国食品药物管理局 (FDA) 已批准 6 种 CAR T 细胞疗法用于治疗骨髓瘤、白血病和淋巴瘤。 2022年12月，FDA批准Adstiladrin，一种基于非复製腺病毒载体的基因疗法，用于治疗患有高危险卡介苗（BCG）无反应的非肌层浸润​​性膀胱癌（NMIBC）的成人患者伴或不伴随乳头状肿瘤的原位癌（CIS）。 2022 年，FDA 批准了 Kimmtrak，这是一种 T 细胞受体疗法，用于治疗眼葡萄膜黑色素瘤中一种罕见的黑色素瘤。随着 FDA 批准用于治疗癌症的细胞和基因疗法数量的增加，这些疗法的产量在过去几年中也有所增加。因此，大量CDMO专注于为癌细胞和基因疗法提供製造服务。

根据应用，细胞和基因治疗製造服务市场分为临床製造和商业製造。商业製造领域在 2022 年占据最大市场份额，预计在预测期内（2020-2030 年）复合年增长率最高，达到 17.1%。在临床效益、耐用性和整体缓解率的共同推动下，CGT 在多个治疗领域提供了巨大的价值。然而，这些疗法尚未获得显着的市场影响力。由于向正确的患者提供正确的治疗存在困难，CGT 的治疗效果被低估，因此，在过去十年中，只有少数基于 CGT 的商业产品进入市场。然而，基于 CGT 的产品处于 3 期临床试验的临床管道表明，在不久的将来批准数量可能会大幅增加。药明康德是一家着名的 CDMO，也是药明康德的全资子公司，宣布于 2021 年 10 月在上海开设新的製程开发和商业製造工厂。该新製造工厂将协助其透过 GMP 商业製造和整合测试服务将在未来几年内支援CGT 产品的商业化。

按最终用户划分，细胞和基因治疗製造服务市场分为製药和生物技术公司以及合约研究组织（CRO）。製药和生物技术领域在 2022 年占据最大市场份额，预计在预测期内（2020-2030 年）复合年增长率最高，达到 17.1%。美国主要製药和生物技术公司致力于提供用于治疗急性和罕见疾病的 CGT，这些疾病对传统方法没有反应，其中包括 ElevateBio 和 Discovery Labs。这些公司致力于创建药品合约开发和製造组织 (CDMO) 的全新分支。他们将透过投资资本利得税相互竞争，并与少数大型服务公司竞争。

目录

第 1 章：简介

  • Insight Partners 研究报告指南
  • 市场区隔

第 2 章：执行摘要

  • 重要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：细胞与基因疗法市场格局

  • 概述
  • PEST分析

第 5 章：细胞和基因治疗市场 - 主要产业动态

  • 主要市场驱动因素：
    • 细胞和基因疗法批准数量的增加
    • 外包细胞和基因治疗製造越来越受欢迎
  • 市场限制
    • 细胞和基因疗法製造成本高昂
  • 市场机会
    • 公司的策略倡议
  • 未来的趋势
    • 细胞和基因治疗製造服务的自动化
  • 影响分析：

第 6 章：细胞与基因治疗市场 - 全球市场分析

  • 细胞和基因治疗市场收入，2022 - 2030

第 7 章：细胞和基因治疗製造服务市场 - 收入和 2030 年预测 - 按类型

  • 概述
  • 细胞和基因治疗製造服务市场收入份额，按类型 2022 年和 2030 年 (%)
  • 细胞疗法
  • 基因治疗

第 8 章：2030 年细胞和基因治疗製造服务市场分析和预测 - 按指标

  • 概述
  • 细胞和基因治疗製造服务市场，按适应症划分 2022 年和 2030 年 (%)
  • 癌症
  • 骨科
  • 其他的

第 9 章：细胞和基因治疗製造服务市场 - 收入和 2030 年预测 -按应用

  • 概述
  • 2022 年和 2030 年细胞和基因治疗製造服务市场收入份额，按应用划分 (%)
  • 临床製造
  • 商业製造

第 10 章：细胞和基因治疗製造服务市场 - 收入和 2030 年预测 - 按最终用户

  • 概述
  • 2022 年和 2030 年细胞和基因治疗製造服务市场收入份额（按最终用户划分）（%）
  • 製药和生物技术公司
  • 合约研究组织 (CRO)

第 11 章：细胞和基因治疗製造服务市场 - 收入和 2030 年预测 - 区域分析

  • 北美：细胞和基因治疗製造服务市场
    • 概述
    • 北美：2020-2030 年细胞和基因治疗製造服务市场（按类型）
      • 北美：细胞和基因治疗製造服务市场，按 Cell Therapy 划分，2020-2030 年
      • 北美：细胞和基因治疗製造服务市场，按 Gene Therapy 划分，2020-2030 年
    • 北美：2020-2030 年细胞和基因治疗製造服务市场（按适应症）
    • 北美：2020-2030 年细胞和基因治疗製造服务市场（按应用）
    • 北美：细胞和基因治疗製造服务市场，按最终用户划分，2020-2030 年
    • 北美：2022 年和 2030 年细胞和基因治疗製造服务市场（按地区）（%）
  • 欧洲：细胞与基因治疗製造服务市场
    • 概述
    • 欧洲：2020-2030 年细胞和基因治疗製造服务市场（按类型）
      • 欧洲：细胞和基因治疗製造服务市场，按细胞疗法划分，2020-2030 年
      • 欧洲：细胞和基因治疗製造服务市场，按 Gene Therapy 划分，2020-2030 年
    • 欧洲：2020-2030 年细胞和基因治疗製造服务市场（按适应症）
    • 欧洲：2020-2030 年细胞和基因治疗製造服务市场（按应用）
    • 欧洲：细胞和基因治疗製造服务市场，按最终用户划分，2020-2030 年
    • 欧洲：细胞和基因治疗製造服务市场，按地区划分，2022 年和 2030 年 (%)
  • 亚太地区：细胞与基因治疗製造服务市场
    • 概述

。

    • 亚太地区：2020-2030 年细胞和基因治疗製造服务市场（按类型）
      • 亚太地区：细胞与基因治疗製造服务市场，依 Cell Therapy 划分，2020-2030 年
      • 亚太地区：细胞和基因治疗製造服务市场，按 Gene Therapy 划分，2020-2030 年
    • 亚太地区：2020-2030 年细胞和基因治疗製造服务市场（按适应症）
    • 亚太地区：2020-2030 年细胞和基因治疗製造服务市场（按应用）
    • 亚太地区：细胞和基因治疗製造服务市场，按最终用户划分，2020-2030 年
    • 亚太地区：2022 年和 2030 年细胞和基因治疗製造服务市场（按地区）（%）
  • 中东和非洲：细胞和基因治疗製造服务市场
    • 概述
    • 中东和非洲：2020-2030 年细胞和基因治疗製造服务市场（按类型）
      • 中东和非洲：细胞和基因治疗製造服务市场，按 Cell Therapy 划分，2020-2030 年
      • 中东和非洲：细胞和基因治疗製造服务市场，按 Gene Therapy 划分，2020-2030 年
    • 中东和非洲：2020-2030 年细胞和基因治疗製造服务市场（按适应症）
    • 中东和非洲：2020-2030 年细胞和基因治疗製造服务市场（按应用）
    • 中东和非洲：细胞和基因治疗製造服务市场，按最终用户划分，2020-2030 年
    • 中东和非洲：2022 年和 2030 年按地区分類的细胞和基因治疗製造服务市场 (%)
  • 南美洲和中美洲：细胞和基因治疗製造服务市场
    • 概述
    • 南美洲和中美洲：2020-2030 年细胞和基因治疗製造服务市场（按类型）
      • 南美洲和中美洲：细胞和基因治疗製造服务市场，按 Cell Therapy 划分，2020-2030 年
      • 南美洲和中美洲：细胞和基因治疗製造服务市场，按 Gene Therapy 划分，2020-2030 年
    • 南美洲和中美洲：细胞和基因治疗製造服务市场，按适应症划分，2020-2030 年
    • 南美洲和中美洲：细胞和基因治疗製造服务市场，按应用分类，2020-2030 年
    • 南美洲和中美洲：细胞和基因治疗製造服务市场，按最终用户划分，2020-2030 年
    • 南美洲和中美洲：细胞和基因治疗製造服务市场，按地区划分，2022 年和 2030 年（%）

第 12 章：细胞与基因疗法製造服务市场 - 产业格局

  • 概述
  • 细胞和基因治疗製造服务市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 13 章：公司简介

  • Thermo Fisher Scientific Inc
  • Merck KGaA
  • Charles River Laboratories International Inc
  • Lonza Group AG
  • WuXi AppTec Co Ltd?
  • Catalent Inc
  • Takara Bio Inc
  • Nikon Corp
  • FUJIFILM Holdings Corp
  • National Resilience Inc
  • Oxford BioMedica Plc
Product Code: TIPRE00024304

The cell and gene therapy manufacturing services market size is expected to grow from US$ 7,581.97 million in 2022 to US$ 26,724.90 million by 2030; it is estimated to register a CAGR of 17.1% during 2022-2030.

The report highlights trends prevailing in the market and the factors driving and hindering the cell and gene therapy manufacturing services market growth. The growth of the market is attributed increase in number of approvals of cell and gene therapies and increasing popularity of outsourcing cell and gene therapy manufacturing. However, high cost of cell and gene therapy manufacturing hinders the market growth.

Strategic Initiatives by Companies

Companies operating in the cell and gene therapy manufacturing services market focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few of the noteworthy developments in the cell and gene therapy manufacturing services market are mentioned below.

In May 2023, Lonza launched the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation devised to optimize and streamline CAR T-cell manufacturing. The TheraPEAK T-VIVO Cell Culture Medium can exhibit a high performance without the need to add human serum or its components, unlike other serum-free media.

In October 2022, Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., the manufacturer of NURTEC ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.

In March 2022, Cellevolve Bio partnered with Seattle Children's Therapeutics to develop and commercialize new multiplex CARs for paediatric cancers. Under the collaboration, the partners will focus on the BrainChild research program, a suite of five multiplex CARs, to treat pediatric central nervous system (CNS) malignancies. In partnership, they would leverage the Seattle Children's Cure Factory facility to conduct early clinical GMP research on new CARs.

In March 2022, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Upon collaboration, the companies had plans of combining Twist's antibody libraries with Kriya's proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya's gene therapy technology.

In February 2022, Edigene Inc. entered into a global license agreement with Boston Children's Hospital (BCH) for intellectual property rights covering the upregulation of foetal haemoglobin by disrupting a key gene. Upregulation of foetal haemoglobin is a potential treatment for many genetic diseases resulting from abnormal haemoglobin structures (hemoglobinopathies), replacing the defective haemoglobin molecule with its foetal version.

In January 2022, FUJIFILM Corporation agreed to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. The facility is readily expandable with the flexibility to produce both clinical and commercial cell therapies, including allogeneic T-cell and CAR T immunotherapies.

In January 2021, Thermo Fisher Scientific Inc acquired Henogen S.A., the Belgium-based viral vector manufacturing business of Groupe Novasep SAS. Henogen provides vaccine and therapeutics manufacturing services to biotechnology companies and large biopharmaceutical customers. With this acquisition, Thermo Fisher Scientific expanded its capabilities in the cell and gene vaccines and therapies category.

Therefore, introducing products such as viral vectors, media for cell therapy manufacturing, and allogeneic T-cells; the development of innovative products targeting various health issues to create new or improved products; and the initiation of new businesses to remain competitive in the market, all, through collaborations and partnerships can help speed up the development of new platforms for cell and gene therapy manufacturing services. Thus, these strategic initiatives create significant growth opportunities in the cell and gene therapy manufacturing services market.

High Cost of Cell and Gene Therapy Manufacturing

As cell and gene therapies involve a complex manufacturing process and use biological components, these therapies are priced exorbitantly. For instance, the cost of Kymriah is ~US$ 475,000, and Yescarta is ~US$ 373,000, respectively. According to the analysis by the Institute for Clinical and Economic Review (ICER), the average cost of a gene therapy ranges US$ 1-2 million per dose. The manufacturing of cell and gene therapies involves various risks, such as the black-box effect, amplified failure, and reduced flexibility. The black-box effect refers to the tasks and processes performed in an automated system; there is no visibility to the process, and the progress status is hidden. Thus, the lack of visibility to the manufacturing processes increases failure and reduces the flexibility to adapt to the manufacturing processes. In addition, the most critical challenge for the manufacturers is to gain product approval from the regulatory bodies-such as FDA and EMA-and ensure patient's safety from the side effects of the therapy.

Furthermore, the cost of consumables and equipment is much higher, which leads to the premium cost of cell therapies. For instance, the cost of the reagent kit offered by Miltenyi Biotec ranges from US$ 500 to US$ 5,000. Similarly, the capital cost of installing the equipment is nearly US$ 2 million. Thus, the challenges pertaining to therapy prices limit the cell and gene therapy manufacturing services market growth.

Cell and Gene Therapy Manufacturing Services Market, By Type Insights

Based on type, the cell and gene therapy manufacturing services market is segmented into cell therapy and gene therapy. Cell therapy is segmented as autologous and allogenic. Further, gene therapy is bifurcated into viral vector and non-viral vector. The cell therapy segment held a larger market share in 2022. However, gene therapy segment is anticipated to register the highest CAGR of 16.6% during the forecast period (2022-2030). Gene therapy is a technique that uses a gene(s) to prevent, treat or cure a medical disorder or disease. Gene therapies often works by replacing a defective, or by adding new copies of a gene that is broken or missing gene in a patient's cells with a healthy version of that gene. Gene therapy can be used to modify cells outside as well as inside the body. A vector is injected carrying the gene directly into the patient when a gene therapy is used to modify cells inside the body. Whereas blood, bone marrow, or another tissue are taken out when gene therapy is used to modify cells outside the body and separate the specific cell types in the lab.

Cell and Gene Therapy Manufacturing Services Market, By Indication-Based Insights

Based on indication, the cell and gene therapy manufacturing services market is divided into cancer, orthopedics, and others. The cancer segment held the largest share of the market in 2022 and same segment is expected to grow at the highest CAGR during the forecast period. The broad field of cell and gene therapy promises many innovative treatments that have the potential to prevent deaths from cancer. According to the April 2022 newsletter by Alliance for Cancer Gene Therapy, Inc., 6 CAR T-cell therapies have been approved by the US Food and Drug Administration (FDA) for the treatment of myeloma, leukemia, and lymphoma. In December 2022, the FDA approved Adstiladrin, a non-replicating adenoviral vector-based gene therapy, for the treatment of adult patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. In 2022, FDA approved Kimmtrak, a T-cell receptor therapy for a rare type of melanoma in the eye-uveal melanoma. As there is an increase in the number of FDA approvals of cell and gene therapy for the treatment of cancer, the production of these therapies has increased in the last several years. Thus, a large number of CDMOs are focusing on providing manufacturing services for cancer cell and gene therapies.

Based on Application, the cell and gene therapy manufacturing services market is categorized into clinical manufacturing and commercial manufacturing. The commercial manufacturing segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR of 17.1% in the market during the forecast period (2020-2030). CGTs provide significant value across multiple therapeutic areas, driven by a combination of clinical benefit, durability, and overall response rate. However, these therapies are yet to gain a significant market reach. The therapeutic gain of CGTs is underestimated due to the difficulty associated with delivering the right therapy to the right patients, and thus, only a few commercial CGTs-based products have reached the market over the past decade. However, the clinical pipeline of CGT-based products in Phase 3 clinical trials indicates the possibility of a dramatic rise in the number of approvals in the near future. WuXi Advanced Therapies Inc., a prominent CDMO and a wholly subsidiary of WuXi AppTec, announced the opening of new process development and commercial manufacturing facility in Shanghai in October 2021. This new manufacturing facility would help it expand its global capacity through GMP commercial manufacturing and integrated testing services that would support the commercialization of CGT products in the coming years.

The cell and gene therapy manufacturing services market, by end user, is categorized into pharmaceutical & biotechnology companies and contract research organizations (CROs). The pharmaceutical and biotechnology segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR of 17.1% in the market during the forecast period (2020-2030). Major US-based pharmaceutical and biotechnology companies committed to offering CGTs intended to treat acute and rare conditions, which are unresponsive to traditional approaches, include ElevateBio and Discovery Labs. These companies are focused on creating a completely new branch of pharmaceutical contract development and manufacturing organizations (CDMOs). They would compete with one another and with a handful of giant services firms by investing in CGTs.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the cell and gene therapy manufacturing services market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the cell and gene therapy manufacturing services market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the cell and gene therapy manufacturing services market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Cell and Gene Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Cell and Gene Therapy Market - Key Industry Dynamics

  • 5.1 Key Market Drivers:
    • 5.1.1 Increase in Number of Approval of Cell and Gene Therapies
    • 5.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Cell and Gene Therapy Manufacturing
  • 5.3 Market Opportunities
    • 5.3.1 Strategic Initiatives by Companies
  • 5.4 Future Trends
    • 5.4.1 Automation of Cell and Gene Therapy Manufacturing Services
  • 5.5 Impact Analysis:

6. Cell and Gene Therapy Market - Global Market Analysis

  • 6.1 Cell and Gene Therapy Market Revenue (US$ Mn), 2022 - 2030

7. Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Type

  • 7.1 Overview
  • 7.2 Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
  • 7.3 Cell Therapy
    • 7.3.1 Overview
    • 7.3.2 Cell Therapy: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.3.2.1 Autologous
        • 7.3.2.1.1 Overview
        • 7.3.2.1.2 Autologous: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.3.2.2 Allogenic
        • 7.3.2.2.1 Overview
        • 7.3.2.2.2 Allogenic: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Gene Therapy
    • 7.4.1 Overview
    • 7.4.2 Gene Therapy: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.4.2.1 Viral Vector
        • 7.4.2.1.1 Overview
        • 7.4.2.1.2 Viral Vector: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.4.2.2 Non-Viral Vector
        • 7.4.2.2.1 Overview
        • 7.4.2.2.2 Non-Viral Vector: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 - by Indication

  • 8.1 Overview
  • 8.2 Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
  • 8.3 Cancer
    • 8.3.1 Overview
    • 8.3.2 Cancer: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Orthopedics
    • 8.4.1 Overview
    • 8.4.2 Orthopedics: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Application

  • 9.1 Overview
  • 9.2 Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
  • 9.4 Clinical Manufacturing
    • 9.4.1 Overview
    • 9.4.2 Clinical Manufacturing: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Commercial Manufacturing
    • 9.5.1 Overview
    • 9.5.2 Commercial Manufacturing: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

10. Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by End User

  • 10.1 Overview
  • 10.2 Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
  • 10.4 Pharmaceutical and Biotechnology Companies
    • 10.4.1 Overview
    • 10.4.2 Pharmaceutical & Biotechnology Companies: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.5 Contract Research Organizations (CROs)
    • 10.5.1 Overview
    • 10.5.2 Contract Research Organizations (CROs): Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

11. Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - Regional Analysis

  • 11.1 North America: Cell and Gene Therapy Manufacturing Services Market
    • 11.1.1 Overview
    • 11.1.2 North America: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.1.3 North America: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 11.1.3.1 North America: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 11.1.3.2 North America: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    • 11.1.4 North America: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    • 11.1.5 North America: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    • 11.1.6 North America: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 11.1.7 North America: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
      • 11.1.7.1 US: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.7.1.1 US: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.1.7.1.1.1 US: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.1.7.1.1.2 US: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.1.7.1.2 US: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.1.7.1.3 US: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.1.7.1.4 US: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.1.7.2 Canada: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.7.2.1 Canada: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.1.7.2.1.1 Canada: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.1.7.2.1.2 Canada: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.1.7.2.2 Canada: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.1.7.2.3 Canada: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.1.7.2.4 Canada: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.1.7.3 Mexico: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.7.3.1 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.1.7.3.1.1 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.1.7.3.1.2 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.1.7.3.2 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.1.7.3.3 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.1.7.3.4 Mexico: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • 11.2 Europe: Cell and Gene Therapy Manufacturing Services Market
    • 11.2.1 Overview
    • 11.2.2 Europe: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.2.3 Europe: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 11.2.3.1 Europe: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 11.2.3.2 Europe: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    • 11.2.4 Europe: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    • 11.2.5 Europe: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    • 11.2.6 Europe: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 11.2.7 Europe: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
      • 11.2.7.1 Germany: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.1.1 Germany: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.1.1.1 Germany: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.1.1.2 Germany: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.1.2 Germany: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.1.3 Germany: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.1.4 Germany: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.2 UK: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.2.1 UK: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.2.1.1 UK: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.2.1.2 UK: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.2.2 UK: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.2.3 UK: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.2.4 UK: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.3 France: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.3.1 France: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.3.1.1 France: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.3.1.2 France: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.3.2 France: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.3.3 France: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.3.4 France: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.4 Italy: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.4.1 Italy: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.4.1.1 Italy: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.4.1.2 Italy: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.4.2 Italy: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.4.3 Italy: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.4.4 Italy: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.5 Spain: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.5.1 Spain: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.5.1.1 Spain: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.5.1.2 Spain: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.5.2 Spain: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.5.3 Spain: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.5.4 Spain: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.2.7.6 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.2.7.6.1 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.2.7.6.1.1 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.2.7.6.1.2 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.2.7.6.2 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.2.7.6.3 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.2.7.6.4 Rest of Europe: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • 11.3 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market
    • 11.3.1 Overview

.

    • 11.3.2 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.3.3 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 11.3.3.1 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 11.3.3.2 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    • 11.3.4 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    • 11.3.5 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    • 11.3.6 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 11.3.7 Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
      • 11.3.7.1 China: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.3.7.1.1 China: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.3.7.1.1.1 China: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.3.7.1.1.2 China: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.3.7.1.2 China: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.3.7.1.3 China: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.3.7.1.4 China: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.3.7.2 Japan: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.3.7.2.1 Japan: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.3.7.2.1.1 Japan: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.3.7.2.1.2 Japan: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.3.7.2.2 Japan: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.3.7.2.3 Japan: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.3.7.2.4 Japan: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.3.7.3 India: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.3.7.3.1 India: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.3.7.3.1.1 India: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.3.7.3.1.2 India: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.3.7.3.2 India: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.3.7.3.3 India: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.3.7.3.4 India: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.3.7.4 Australia: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.3.7.4.1 Australia: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.3.7.4.1.1 Australia: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.3.7.4.1.2 Australia: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.3.7.4.2 Australia: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.3.7.4.3 Australia: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.3.7.4.4 Australia: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.3.7.5 South Korea: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.3.7.5.1 South Korea: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.3.7.5.1.1 South Korea: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.3.7.5.1.2 South Korea: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.3.7.5.2 South Korea: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.3.7.5.3 South Korea: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.3.7.5.4 South Korea: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.3.7.6 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.3.7.6.1 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.3.7.6.1.1 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.3.7.6.1.2 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.3.7.6.2 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.3.7.6.3 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.3.7.6.4 Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • 11.4 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market
    • 11.4.1 Overview
    • 11.4.2 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.4.3 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 11.4.3.1 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 11.4.3.2 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    • 11.4.4 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    • 11.4.5 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    • 11.4.6 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 11.4.7 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
      • 11.4.7.1 South Africa: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.4.7.1.1 South Africa: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.4.7.1.1.1 South Africa: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.4.7.1.1.2 South Africa: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.4.7.1.2 South Africa: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.4.7.1.3 South Africa: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.4.7.1.4 South Africa: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.4.7.2 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.4.7.2.1 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.4.7.2.1.1 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.4.7.2.1.2 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.4.7.2.2 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.4.7.2.3 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.4.7.2.4 Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.4.7.3 UAE: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.4.7.3.1 UAE: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.4.7.3.1.1 UAE: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.4.7.3.1.2 UAE: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.4.7.3.2 UAE: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.4.7.3.3 UAE: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.4.7.3.4 UAE: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.4.7.4 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.4.7.4.1 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.4.7.4.1.1 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.4.7.4.1.2 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.4.7.4.2 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.4.7.4.3 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.4.7.4.4 Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • 11.5 South & Central America: Cell and Gene Therapy Manufacturing Services Market
    • 11.5.1 Overview
    • 11.5.2 South & Central America: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 11.5.3 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 11.5.3.1 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 11.5.3.2 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    • 11.5.4 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    • 11.5.5 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    • 11.5.6 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 11.5.7 South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
      • 11.5.7.1 Brazil: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.5.7.1.1 Brazil: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.5.7.1.1.1 Brazil: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.5.7.1.1.2 Brazil: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.5.7.1.2 Brazil: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.5.7.1.3 Brazil: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.5.7.1.4 Brazil: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.5.7.2 Argentina: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.5.7.2.1 Argentina: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.5.7.2.1.1 Argentina: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.5.7.2.1.2 Argentina: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.5.7.2.2 Argentina: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.5.7.2.3 Argentina: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.5.7.2.4 Argentina: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 11.5.7.3 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.5.7.3.1 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 11.5.7.3.1.1 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 11.5.7.3.1.2 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 11.5.7.3.2 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 11.5.7.3.3 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 11.5.7.3.4 Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)

12. Cell and Gene Therapy Manufacturing Services Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Cell and Gene Therapy Manufacturing Services Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Thermo Fisher Scientific Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Merck KGaA
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Charles River Laboratories International Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Lonza Group AG
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 WuXi AppTec Co Ltd?
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Catalent Inc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Takara Bio Inc
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Nikon Corp
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 FUJIFILM Holdings Corp
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 National Resilience Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Oxford BioMedica Plc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

List Of Tables

  • Table 1. Cell and Gene Therapy Market Segmentation
  • Table 2. Recent Organic Growth Strategies in Cell and Gene Therapy Manufacturing Services Market
  • Table 3. Recent Inorganic Growth Strategies in the Cell and Gene Therapy Manufacturing Services Market

List Of Figures

  • Figure 1. Cell and Gene Therapy Market Segmentation, By Geography
  • Figure 2. PEST Analysis
  • Figure 3. Cell and Gene Therapy Market - Key Industry Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. Cell and Gene Therapy Market Revenue (US$ Mn), 2022 - 2030
  • Figure 6. Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
  • Figure 7. Cell Therapy: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Autologous: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Allogenic: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Gene Therapy: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Viral Vector: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Non-Viral Vector: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
  • Figure 14. Cancer: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Orthopedics: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Others: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 18. Clinical Manufacturing: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Commercial Manufacturing: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 21. Pharmaceutical & Biotechnology Companies: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. Contract Research Organizations (CROs): Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. North America: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
  • Figure 24. North America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. North America: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  • Figure 26. US: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 27. Canada: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 28. Mexico: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. Europe: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
  • Figure 30. Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 31. Europe: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  • Figure 32. Germany: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 33. UK: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 34. France: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 35. Italy: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 36. Spain: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 37. Rest of Europe: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 38. Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
  • Figure 39. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 40. Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  • Figure 41. China: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 42. Japan: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 43. India: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 44. Australia: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 45. South Korea: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 46. Rest of Asia Pacific: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 47. Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
  • Figure 48. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 49. Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  • Figure 50. South Africa: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 51. Saudi Arabia: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 52. UAE: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 53. Rest of Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 54. South & Central America: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
  • Figure 55. South & Central America Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 56. Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  • Figure 57. Brazil: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 58. Argentina: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 59. Rest of South & Central America: Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 60. Growth Strategies in Cell and Gene Therapy Manufacturing Services Market